Related references
Note: Only part of the references are listed.An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials
Jie Yu et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Boris Bikbov et al.
LANCET (2020)
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Hiddo J. L. Heerspink et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation
Shiho Komatsu et al.
ENDOCRINE JOURNAL (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma
Teruo Jojima et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake
Kosuke Kaji et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Hiddo J. L. Heerspink et al.
KIDNEY INTERNATIONAL (2018)
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
Christoph Wanner et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma
Claudio R. Scafoglio et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Examination of Cause-of-Death Data Quality Among New York City Deaths Due to Cancer, Pneumonia, or Diabetes From 2010 to 2014
Laura Falci et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2018)
Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
Hiddo J. L. Heerspink et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma
Haoyu Kuang et al.
MEDICAL SCIENCE MONITOR (2017)
Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice
Annika Astrand et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Giuseppe Daniele et al.
DIABETES CARE (2016)
Association of Kidney Disease Measures with Cause-Specific Mortality: The Korean Heart Study
Yejin Mok et al.
PLOS ONE (2016)
Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
David M. Charytan et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Cause of Death in Patients with Reduced Kidney Function
Stephanie Thompson et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis
Suetonia C. Palmer et al.
LANCET (2015)
Chronic Kidney Disease and Risk of Death from Infection
Henry E. Wang et al.
AMERICAN JOURNAL OF NEPHROLOGY (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent et al.
LANCET (2011)
Problems with proper completion and accuracy of the cause-of-death statement
AES Sehdev et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
Share Paper
